Badizadegan K, Thompson K
PLOS Glob Public Health. 2025; 5(2):e0004168.
PMID: 39919149
PMC: 11805368.
DOI: 10.1371/journal.pgph.0004168.
Badizadegan N, Wassilak S, Estivariz C, Wiesen E, Burns C, Bolu O
Pathogens. 2024; 13(9).
PMID: 39338995
PMC: 11435063.
DOI: 10.3390/pathogens13090804.
Thompson K, Badizadegan K
Pathogens. 2024; 13(6).
PMID: 38921733
PMC: 11206708.
DOI: 10.3390/pathogens13060435.
Sun Y, Keskinocak P, Steimle L, Kovacs S, Wassilak S
Vaccine X. 2024; 18:100476.
PMID: 38617838
PMC: 11011220.
DOI: 10.1016/j.jvacx.2024.100476.
Kalkowska D, Wassilak S, Wiesen E, Estivariz C, Burns C, Badizadegan K
Gates Open Res. 2023; 7:55.
PMID: 37547300
PMC: 10403636.
DOI: 10.12688/gatesopenres.14511.1.
Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
Kalkowska D, Wassilak S, Wiesen E, Burns C, Pallansch M, Badizadegan K
Risk Anal. 2023; 44(2):366-378.
PMID: 37344934
PMC: 10733544.
DOI: 10.1111/risa.14158.
Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.
Kalkowska D, Wiesen E, Wassilak S, Burns C, Pallansch M, Badizadegan K
Risk Anal. 2023; 44(2):379-389.
PMID: 37344376
PMC: 10733542.
DOI: 10.1111/risa.14159.
Nonlinear Dynamics of the Introduction of a New SARS-CoV-2 Variant with Different Infectiousness.
Gonzalez-Parra G, Arenas A
Mathematics (Basel). 2023; 9(13).
PMID: 37022323
PMC: 10072858.
DOI: 10.3390/math9131564.
Outbreak response strategies with type 2-containing oral poliovirus vaccines.
Kalkowska D, Wassilak S, Pallansch M, Burns C, Wiesen E, Durry E
Vaccine. 2022; 41 Suppl 1:A142-A152.
PMID: 36402659
PMC: 10284582.
DOI: 10.1016/j.vaccine.2022.10.060.
Using integrated modeling to support the global eradication of vaccine-preventable diseases.
Tebbens R, Thompson K
Syst Dyn Rev. 2021; 34(1-2):78-120.
PMID: 34552305
PMC: 8455164.
DOI: 10.1002/sdr.1589.
Stopping a polio outbreak in the midst of war: Lessons from Syria.
Mbaeyi C, Moran T, Wadood Z, Ather F, Sykes E, Nikulin J
Vaccine. 2021; 39(28):3717-3723.
PMID: 34053791
PMC: 10347301.
DOI: 10.1016/j.vaccine.2021.05.045.
Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Kalkowska D, Pallansch M, Wassilak S, Cochi S, Thompson K
Vaccine. 2021; 41 Suppl 1:A136-A141.
PMID: 33994237
PMC: 11027208.
DOI: 10.1016/j.vaccine.2021.04.061.
Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.
Thompson K, Kalkowska D
Expert Rev Vaccines. 2020; 19(7):661-686.
PMID: 32741232
PMC: 7497282.
DOI: 10.1080/14760584.2020.1791093.
Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
Thompson K, Kalkowska D
Risk Anal. 2020; 41(2):229-247.
PMID: 32339327
PMC: 7983882.
DOI: 10.1111/risa.13484.
Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
Tebbens R, Thompson K
Expert Rev Vaccines. 2018; 17(8):739-751.
PMID: 30056767
PMC: 6168953.
DOI: 10.1080/14760584.2018.1506333.
Assessing the impact of the Lebanese National Polio Immunization Campaign using a population-based computational model.
Alawieh A, Sabra Z, Langley E, Bizri A, Hamadeh R, Zaraket F
BMC Public Health. 2017; 17(1):902.
PMID: 29178859
PMC: 5702188.
DOI: 10.1186/s12889-017-4909-0.
Modelling Risk to US Military Populations from Stopping Blanket Mandatory Polio Vaccination.
Burgess C, Burgess A, McMullen K
Comput Math Methods Med. 2017; 2017:7981645.
PMID: 29104608
PMC: 5618742.
DOI: 10.1155/2017/7981645.
A Risk Analysis Approach to Prioritizing Epidemics: Ebola Virus Disease in West Africa as a Case Study.
Ajisegiri W, Chughtai A, MacIntyre C
Risk Anal. 2017; 38(3):429-441.
PMID: 28810081
PMC: 5949606.
DOI: 10.1111/risa.12876.
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
Tebbens R, Pallansch M, Wassilak S, Cochi S, Thompson K
BMC Infect Dis. 2016; 16:137.
PMID: 27009272
PMC: 4806487.
DOI: 10.1186/s12879-016-1465-7.
Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.
Kalkowska D, Tebbens R, Grotto I, Shulman L, Anis E, Wassilak S
J Infect Dis. 2014; 211(11):1800-12.
PMID: 25505296
PMC: 7887763.
DOI: 10.1093/infdis/jiu674.